-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

183 Piezo1-Mediated Thromboprotection Is Markedly Influenced By Laminar Shear Forces in Vitro and in Vivo

Program: Oral and Poster Abstracts
Type: Oral
Session: 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets and Endothelium in Thrombotic Disorders
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Research, Fundamental Science, Thromboembolism, Diseases, Infectious Diseases, Thrombotic disorders, Biological Processes, Molecular biology
Saturday, December 7, 2024: 2:30 PM

Kelsey D Sack, MD, PhD1,2, Calum MacRae, MD, PhD3* and Robert Flaumenhaft, MD, PhD4

1Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Belmont, MA
2Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
3Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
4Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

A system of mechanosensing mechanisms promote a fully-differentiated, quiescent endothelium through stimulation of flow-sensitive transcriptional activation mediated in part by endothelial calcium channels. Loss of laminar flow can interrupt these mechanisms leading to a partial endothelial-mesenchymal transition and promoting a prothrombotic phenotype. Piezo1 is the most abundant calcium channel in the endothelium. It can be activated by the pharmacological agonist Yoda1. We evaluated the thromboprotective effect of Yoda1 on inflammation-induced prothrombotic changes in endothelium in static conditions, laminar flow, non-laminar flow, and in vivo. (1) In static conditions, exposure to as little as 0.25 μM Yoda1 reduced TNFα-mediated factor Xa generation, while concentrations greater than 1 μM increased caspase-3 expression and cell rounding consistent with apoptosis. Yoda1 (0.25 μM) reduced TNFα-mediated factor Xa generation in human umbilical vein endothelial cells by 79% (p<0.001) and in human microvascular endothelial cells of lung origin by 85% (p<0.001), induced thrombomodulin expression, and prevented TNFα-induced tissue factor (TF) and NF-κB expression. This Yoda1 effect is specific for Piezo1. In particular, following siRNA Piezo1 knockdown, endothelial cells exposed to TNFα and Yoda1 failed to potentiate thrombomodulin, showing only 16% (p<0.001) of thrombomodulin expression compared to control siRNA transfected cells. Conversely, the Piezo1 siRNA/Yoda1/TNFα exposed cells potentiated pro-thrombotic factors NF-κB (2.2-fold, p<0.0083) and TF (4.8-fold, p<0.0002) compared to control siRNA exposed cells. Knockdown of KLF4 similarly reversed the protective effects of Yoda1 in the TNFα-induced factor Xa generation assay, indicating that KLF4 mediates thromboprotection downstream of Piezo1. (2) Under the influence of laminar flow, dose finding studies demonstrated that 6-fold higher Yoda1 concentrations were required to attenuate TNFα-mediated FXa generation and TF expression in endothelial cells exposed to mechanical flow compared to static conditions. Under flow, Yoda1 (1.5 μM) exposure resulted in a 63% reduction in FXa generation (p<0.05) and attenuated TF protein levels by 10-fold (p<0.05). Interestingly, under flow, this higher Yoda1 concentration had no effect on endothelial cell morphology or survival. (3) In non-laminar flow conditions, still higher concentrations of Yoda1 were required to achieve protection against the thromboinflammatory transformation. Specifically, 2.5 μM Yoda1 (10-fold higher than static conditions) resulted in a 68% reduction (p<0.05) in TNFα-mediated FXa generation and TF reduction trended towards attenuation (2-fold reduction). No apoptosis was observed. (4) To assess the impact of Yoda1 on thromboprotection in vivo, we used thrombomodulin and EPCR as endothelial-specific readouts for Yoda1-sensitive antithrombotic endothelial changes. Mice were injected with vehicle or Yoda1 at 213 μg/kg, 444 μg/kg, or 533 μg/kg. At 533 μg/kg, but not lower concentrations, we found significant (p<0.05) increases in the expression of thrombomodulin (5-fold) and EPCR (2.4 fold) in pulmonary tissue samples. In mice exposed to both Yoda1 and LPS, pulmonary tissue retained increased levels of thrombomodulin (2-fold, p<0.05) and liver fibrin levels trended lower (0.71-fold) compared to mice exposed to LPS and vehicle. Yoda1 injection inhibited fibrin formation (p<0.01) in a laser-injury model. These findings support our hypothesis that pharmacologic Piezo1 agonism has a potent effect in enhancing the quiescent, antithrombotic endothelial cell barrier. The data also demonstrate that shear forces dramatically modify the effect of agonist-mechanoreceptor pharmacological interactions on endothelial morphology, viability, and prothrombotic phenotypes. Such shear-dependent changes in agonist sensitivity are likely related to modulation of Piezo1 conformation and/or cellular distribution, which are sensitive to shear, although alternative explanations cannot be ruled out. These studies underscore the importance of flow-mediated alterations in agonist-channel interactions in developing antithrombotics targeting mechanoreceptors.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH